Trexquant Investment’s Seres Therapeutics MCRB Stock Holding History

Trexquant Investment’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-886	Closed	-$126K	–	1723
2022 Q1	$126K	Sell	886 -1,906	-68%	-$293K	0.01%	1263
2021 Q4	$465K	Buy	2,792 +1,905	+215%	+$303K	0.03%	682
2021 Q3	$123K	Buy	+887	New	+$174K	0.01%	1032
2021 Q2	–	Sell	-687	Closed	-$283K	–	1327
2021 Q1	$283K	Sell	687 -45	-6%	-$20.7K	0.03%	787
2020 Q4	$359K	Buy	+732	New	+$429K	0.04%	591
2020 Q3	–	Sell	-3,339	Closed	-$318K	–	1412
2020 Q2	$318K	Buy	+3,339	New	+$293K	0.02%	851
2018 Q1	–	Sell	-715	Closed	-$145K	–	1248
2017 Q4	$145K	Buy	+715	New	+$147K	0.02%	980
2017 Q1	–	Sell	-1,296	Closed	-$257K	–	1218
2016 Q4	$257K	Buy	1,296 +772	+147%	+$168K	0.04%	715
2016 Q3	$129K	Buy	+524	New	+$184K	0.03%	677

Other funds holding MCRB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Trexquant Investment's MCRB Position: Q2 2022 in Review

Trexquant Investment sold out of Seres Therapeutics (MCRB) in Q2 2022, closing a stake of 886 shares — an estimated $126K sold.

Trexquant Investment first reported a position in MCRB in Q3 2016 and held it in 9 quarters. The position peaked at $465K in Q4 2021. 123 funds tracked by Wall St. Rank hold MCRB as of Q2 2022.

Trexquant Investment reported no remaining Seres Therapeutics position as of Q2 2022 after selling out during the quarter.
Trexquant Investment sold 886 Seres Therapeutics shares in Q2 2022, an estimated $126K.
Trexquant Investment first reported a position in Seres Therapeutics in Q3 2016 and held it in 9 quarters.
Trexquant Investment's Seres Therapeutics position peaked at $465K in Q4 2021.
123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2022.

Based on Trexquant Investment's 13F filing for Q2 2022, filed 11 Aug 2022.